Press release content from Accesswire. The AP news staff was not involved in its creation.
Relief Reports 2020 Financial Results and Provides Business Update
April 15, 2021 GMT
GENEVA, SWITZERLAND / ACCESSWIRE / April 15, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (“Relief” or the “Company”), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat COVID-19 induced lung injury, today announced its 2020 financial results for the year ended December 31, 2020 and provided a business update.
“The past year has been an incredibly productive and rewarding one for all of us at Relief,” said Raghuram (Ram) Selvaraju, Chairman of the Board. “We have had an opportunity to make a true difference in fighting the ongoing COVID-19 pandemic with the development of RLF-100(TM) to treat critically ill patients. With the goal of bringing this potential treatment to patients as expeditiously as possible, we en
Relief Therapeutics Holding AG: Relief Reports 2020 Financial Results and Provides Business Update
Relief or the
Company ), a biopharmaceutical company with its lead compound RLF-100
TM (aviptadil) in advanced clinical development to treat COVID-19 induced lung injury, today announced its 2020 financial results for the year ended December 31, 2020 and provided a business update. The past year has been an incredibly productive and rewarding one for all of us at Relief, said
Raghuram (Ram) Selvaraju, Chairman of the Board. We have had an opportunity to make a true difference in fighting the ongoing COVID-19 pandemic with the development of RLF-100 to treat critically ill patients. With the goal of bringing this potential treatment to patients as expeditiously as possible, we entered into important partnerships and made key hires, adding executives to our team who have strong expertise in important areas such as clinical development, regulatory and commercialization.
E-Mail
IMAGE: A dense-core amyloid-beta plaque (red) surrounded by microglia that lack TAM receptors (white) in the brain of a mouse with Alzheimer s disease view more
Credit: Salk Institute
LA JOLLA (April 15, 2021) One of the characteristic hallmarks of Alzheimer s disease (AD) is the buildup of amyloid-beta plaques in the brain. Most therapies designed to treat AD target these plaques, but they ve largely failed in clinical trials. New research by Salk scientists upends conventional views of the origin of one prevalent type of plaque, indicating a reason why treatments have been unsuccessful.
The traditional view holds that the brain s trash-clearing immune cells, called microglia, inhibit the growth of plaques by eating them. The Salk scientists show instead that microglia promote the formation of dense-core plaques, and that this action sweeps wispy plaque material away from neurons, where it causes cell death. The research, which was published in
Health experts are urging EU policymakers and legislators to review the EU’s legal data protection framework, the GDPR, which is hampering the sharing of pseudonymised health data outside the EU and the European Economic Area (EEA).
According to a new report, released on 8 April, the sharing of health data with researchers outside the EU/EEA is sorely needed to enhance international research collaboration in the public sector, thereby maximising health benefits for European citizens.
However, it is currently hindered by a restrictive legal framework, authors warn.
The General Data Protection Regulation (GDPR) provides the legal framework for sharing pseudonymised health data with researchers outside the EU/EEA, including within the public sector.
Moderna to take mRNA flu and HIV vaccines into Phase 1 trials this year Moderna will take mRNA flu and HIV vaccines into Phase 1 trials this year, as well as beginning a pivotal Phase 3 study for its cytomegalovirus (CMV) vaccine candidate.
A Phase 1 study for a RSV vaccine candidate is also under way.
As part of its Vaccine Day this week, the company has updated its vaccine developement timeline and unveiled results from early stage mRNA vaccine trials.
HIV vaccines: mRNA-1644 and mRNA-1574
Moderna expects to begin three phase 1 clinical trials for two HIV vaccine candidates, mRNA-1644 and mRNA-1574, in 2021.
mRNA-1644 is a novel approach to HIV vaccine strategy in humans designed to elicit broadly neutralizing HIV-1 antibodies (bNAbs). It is being developed in collaboration with the International AIDS Vaccine Initiative (IAVI) and the Bill and Melinda Gates Foundation (BMGF). A Phase 1 study for the candidate will use iterative human testing t